Casopitant (INNTooltip International Nonproprietary Name),[1]: 208  former tentative trade names Rezonic (U.S.) and Zunrisa (Europe), is an NK1 receptor antagonist which was undergoing research for the treatment of chemotherapy-induced nausea and vomiting.

[2] In July 2008, the company filed a marketing authorisation application with the European Medicines Agency.

The application was withdrawn and development was discontinued in September 2009 because GlaxoSmithKline decided that further safety assessment was necessary.

[2][4] However, a 2022 review listed casopitant as under development as a potential novel antidepressant for the treatment of major depressive disorder, with a phase 2 clinical trial having been completed.

You can help Wikipedia by expanding it.This drug article relating to the nervous system is a stub.